Principles of Organic Medicinal Chemistry Is Concerned with Chemistry, Synthesis, Struc- Ture Activity Relationships, Properties and Uses of Drugs of Carbon Compounds

Total Page:16

File Type:pdf, Size:1020Kb

Principles of Organic Medicinal Chemistry Is Concerned with Chemistry, Synthesis, Struc- Ture Activity Relationships, Properties and Uses of Drugs of Carbon Compounds This page intentionally left blank Copyright © 2005, New Age International (P) Ltd., Publishers Published by New Age International (P) Ltd., Publishers All rights reserved. No part of this ebook may be reproduced in any form, by photostat, microfilm, xerography, or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of the publisher. All inquiries should be emailed to [email protected] ISBN (13) : 978-81-224-2485-0 PUBLISHING FOR ONE WORLD NEW AGE INTERNATIONAL (P) LIMITED, PUBLISHERS 4835/24, Ansari Road, Daryaganj, New Delhi - 110002 Visit us at www.newagepublishers.com PREFACE Principles of Organic Medicinal Chemistry is concerned with chemistry, synthesis, struc- ture activity relationships, properties and uses of drugs of carbon compounds. This book has primarily been written with the aim of meeting the needs and interests of undergraduate and graduate pharmacy course according to syllabi of various Indian Universities. The book is a concise form covering all newer drugs will help the readers to a great extent. Though several books are available on medicinal chemistry, the material in most of them is present in a diffused form or highly specialized. In the ever expanding knowledge of the chemistry of drugs it is very difficult to go through the various textbooks, journals, and pharmacopoeias. The major objective of writing this book is to present the information in a lucid, condensed and cohesive form, to cater specially the needs of undergraduate and graduate students of pharmacy. It is impossible to express my indebtedness to those authors of various books, articles and monographs mentioned in bibliography, which became a major source of information for writing this text. I wish to recall my gratitude to Sri Y.V. Anjaneyulu, Chairman, Chalapathi Education Society, Guntur, members of Siddhartha Academy, Vijayawada, staff members of Chalapathi Institute of Pharmaceutical Sciences, Guntur, and Principal and staff members of KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada for their kind cooperation. I am also wish to acknowledge indebtedness to all who have assisted with the completion of the book. The cooperation of publishers, Messrs New Age International (P) Limited and publishers is very much appreciated in bringing out this book. The contribution that I received by sus- tained cooperation of my wife and daughter cann’t be ignored. I have made every effort to avoid printing errors. However, despite best efforts, some might have crept in inadvertently. I shall be oblished if these are brought to my notice. Con- structive suggestions, comments and criticism on the subject matter of the book will be grate- fully acknowledged, as they will certainly help to improve future editions of the book. It is hoped that the book will be received favorably as an effective text book by both students and teachers of pharmacy, science and medical scientists. Author C-8—N-CHEMI\TITLE.PM5 3 This page intentionally left blank CONTENTS 1. Introduction to medicinal chemistry ........................................................................... 1 2. General priciples of drug action ................................................................................... 3 3. Physico chemical properties of organic medicinal agents ........................................ 14 4. Chemistry of prodrugs ................................................................................................ 31 5. Drug metabolism ......................................................................................................... 41 6. General anesthetics .................................................................................................... 52 7. Sedative-hypnotic drugs ............................................................................................. 61 8. Psychoactive drugs...................................................................................................... 77 9. Antiepileptic agents .................................................................................................. 102 10. Cholinergic and anticholinergic drugs .................................................................... 121 11. Adrenergic drugs ....................................................................................................... 149 12. Adrenoreceptor blocking drugs ................................................................................ 170 13. Skeletal muscle relaxants ........................................................................................ 180 14. Antihistamines .......................................................................................................... 184 15. Narcotic analgesics ................................................................................................... 211 16. Narcotic antagonists ................................................................................................. 225 17. Antitussives ............................................................................................................... 229 18. Non-steroidal antiinflammatory drugs ................................................................... 232 19. Local anesthetics ....................................................................................................... 249 20. Diuretics .................................................................................................................... 259 21. Hypoglycemic agents ................................................................................................ 270 22. Thyroid and antithyroid drugs................................................................................. 282 Practice Questions ..................................................................................................... 290 References .................................................................................................................. 315 Index .......................................................................................................................... 317 C-8—N-CHEMI\TITLE.PM5 4 This page intentionally left blank Introduction to Medicinal 1 Chemistry The subject of medicinal chemistry explains the design and production of compounds that can be used for the prevention, treatment or cure of human and animal diseases. Medicinal chem- istry includes the study of already existing drugs, of their biological properties and their struc- ture-activity relationships. Medicinal chemistry was defined by IUPAC specified commission as “it concerns the discovery, the development, the identification and the interpretation of the mode of action of biologically active compounds at the molecular level”. Medicinal chemistry covers the following stages: (i) In the first stage new active substances or drugs are identified and prepared from natural sources, organic chemical reactions or biotechnological processes. They are known as lead molecules. (ii) The second stage is optimization of lead structure to improve potency, selectivity and to reduce toxicity. (iii) Third stage is development stage, which involves optimization of synthetic route for bulk production and modification of pharmacokinetic and pharmaceutical properties of active substance to render it clinically useful. Medicinal chemistry is the application of chemical research techniques to the synthesis of pharmaceuticals. During the early stages of medicinal chemistry development, scientists were primarily concerned with the isolation of medicinal agents found in plants. Today, scien- tists in this field are also equally concerned with the creation of new synthetic compounds as drugs. Medicinal chemistry is almost always geared toward drug discovery and development. Medicinal chemists apply their chemistry training to the process of synthesizing new pharmaceuticals. They also work on improving the process by which other pharmaceuticals are made. Most chemists work with a team of scientists from different disciplines, including biologists, toxicologists, pharmacologists, theoretical chemists, microbiologists, and biopharmacists. Together this team uses sophisticated analytical techniques to synthesize and test new drug products and to develop the most cost-effective and eco-friendly means of pro- duction. 1 2 General Principles of Drug Action DEFINITION OF DRUGS A very broad definition of a drug would include “all chemicals other than food that affect living processes.” If the affect helps the body, the drug is a medicine. However, if a drug causes a harmful effect on the body, the drug is a poison. The same chemical can be a medicine and a poison depending on conditions of use and the person using it. Another definition would be “medicinal agents used for diagnosis, prevention, treatment of symptoms, and cure of diseases.” Contraceptives would be outside of this definition unless pregnancy was considered a disease. All drugs have the potential for producing more than one response. Some adverse drug responses which are unavoidable are appearing at therapeutic doses are termed as side effects. Incontrast, adverse drug effects appearing at extreme drug doses are described as toxic effects. CLASSIFICATION OF DRUGS Drugs can be classified according to various criteria: 1. By origin—sources of drugs Drugs may be obtained from 1. Plants 2. Animals 3. Minerals or 4. Microorganisms. The drugs may also be semisynthetic or synthetic compounds. The sources of drugs are summa-
Recommended publications
  • Multidimensional Analysis of Extended Molecular Dynamics Simulations Shows the Complexity of Signal
    bioRxiv preprint doi: https://doi.org/10.1101/604793; this version posted April 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. TITLE Multidimensional analysis of extended molecular dynamics simulations shows the complexity of signal transduction by the histamine H3 membrane receptor Short title: Molecular dynamics of signal transduction AUTHORS Herrera-Zuniga LD1,4, Moreno-Vargas LM2,4, Correa-Basurto J1,3, Prada D2, Curmi P1, Arrang, JM4, Maroun, RC1,4* 1 SABNP, UMR-S U1204, INSERM/Université d’Evry-Val d’Essonne/Université Paris-Saclay, 91025 Evry, FRANCE 2 Computational Biology and Drug Design Research Unit. Federico Gomez Children's Hospital of Mexico City, MEXICO 3 Laboratory for the Design and Development of New Drugs and Biotechnological Innovation) SEPI-ESM, MEXICO 4 INSERM U894, Paris, FRANCE *Corresponding author 1 bioRxiv preprint doi: https://doi.org/10.1101/604793; this version posted April 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT In this work, we study the mechanisms of activation and inactivation of signal transduction by the histamine H3 receptor (H3R), a 7TM GPCR through extended molecular dynamics (MD) simulations of the receptor embedded in a hydrated double layer of dipalmitoyl phosphatidyl choline (DPPC), a zwitterionic poly-saturated ordered lipid. Three systems were prepared: the apo H3R, representing the constitutively active receptor; and the holo-systems: the H3R coupled to an antagonist/inverse agonist (ciproxifan) and representing the inactive state of the receptor; and the H3R coupled to the endogenous agonist histamine and representing the active state of the receptor.
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017
    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
    [Show full text]
  • COMBINED LIST of Particularly Hazardous Substances
    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
    [Show full text]
  • Eslicarbazepine Acetate: a New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
    Drugs R D DOI 10.1007/s40268-017-0197-5 REVIEW ARTICLE Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures 1 1 1 Graciana L. Galiana • Angela C. Gauthier • Richard H. Mattson Ó The Author(s) 2017. This article is an open access publication Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family Key Points that is currently approved as adjunctive therapy and monotherapy for partial-onset (focal) seizures. The drug Eslicarbazepine acetate is an effective and safe enhances slow inactivation of voltage-gated sodium chan- treatment option for partial-onset seizures as nels and subsequently reduces the activity of rapidly firing adjunctive therapy and monotherapy. neurons. Eslicarbazepine acetate has few, but some, drug– drug interactions. It is a weak enzyme inducer and it Eslicarbazepine acetate improves upon its inhibits cytochrome P450 2C19, but it affects a smaller predecessors, carbamazepine and oxcarbazepine, by assortment of enzymes than carbamazepine. Clinical being available in a once-daily regimen, interacting studies using eslicarbazepine acetate as adjunctive treat- with a smaller range of drugs, and causing less side ment or monotherapy have demonstrated its efficacy in effects. patients with refractory or newly diagnosed focal seizures. The drug is generally well tolerated, and the most common side effects include dizziness, headache, and diplopia. One of the greatest strengths of eslicarbazepine acetate is its ability to be administered only once per day. Eslicar- 1 Introduction bazepine acetate has many advantages over older anti- epileptic drugs, and it should be strongly considered when Epilepsy is a common neurological disorder affecting over treating patients with partial-onset epilepsy.
    [Show full text]
  • Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW
    Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW Name of Medicine / Trimipramine (Surmontil®) Class (generic and brand) Licensed indication(s) Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. Licensed dose(s) Adults: For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day. Elderly: 10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response. Children: Not recommended. Purpose of Document To review information currently available on this class of medicines, give guidance on potential use and assign a prescribing classification http://www.cambsphn.nhs.uk/CJPG/CurrentDrugClassificationTable.aspx Annual cost (FP10) 10mg three times daily: £6,991 25mg three times daily: £7,819 150mg daily: £7,410 300mg daily: £14,820 Alternative Treatment Options within Class Tricyclic Annual Cost CPCCG Formulary Classification Antidepressant (FP10) Amitriptyline (75mg) Formulary £36 Lofepramine (140mg) Formulary £146 Imipramine (75mg) Non-formulary £37 Clomipramine (75mg) Non-formulary £63 Trimipramine (75mg). TBC £7,819 Nortriptyline (75mg) Not Recommended (pain) £276 Doxepin (150mg) TBC £6,006 Dosulepin (75mg) Not Recommended (NICE DO NOT DO) £19 Dosages are based on possible maintenance dose and are not equivalent between medications Recommendation It is recommended to Cambridgeshire and Peterborough CCG JPG members and through them to local NHS organisations that the arrangements for use of trimipramine are in line with restrictions agreed locally for drugs designated as NOT RECOMMENDED:.
    [Show full text]
  • Download Download
    MM Matin et al. Medical Research Archives vol 8 issue 7. Medical Research Archives RESEARCH ARTICLE 2e`1 PASS Predication, Antiviral, in vitro Antimicrobial, and ADMET Studies of Rhamnopyranoside Esters Authors Mohammed M Matin1, Mohammad HO Roshid2, Sreebash C Bhattacharjee3 and Abul KMS Azad4 Affiliations 1 Bioorganic & Medicinal Chemistry Laboratory, Department of Chemistry, University of Chittagong, Chattogram-4331, Bangladesh 2 Department of Anaesthesia and Intensive Care Medicine, Chattogram Medical College, Chattogram- 4203, Bangladesh 3 Chemical Research Division, Bangladesh Council of Scientific & Industrial Research (BCSIR) Laboratories, Chattogram-4220, Bangladesh 4 Department of Chemistry, Chattogram Govt. College, Chattogram-4203, Bangladesh Corresponding Author: MM Matin E-mail address: [email protected] Tel.: +88 01716 839689. Abstract Sugar derived esters (SEs) with potential antimicrobial activity were found to be a better choice to solve the multidrug resistant (MDR) pathogens due to improved antimicrobial efficacy, biodegradability, non-toxic, and non-allergic properties. In this context, a series of benzyl -L- rhamnopyranoside esters with different chain length (C2-C18) were employed for PASS predication, antiviral, and in vitro antimicrobial activity test. The in vitro antimicrobial tests against four bacterial, and four fungal pathogens along with PASS predication indicated that these sugar esters acted as better antifungals as compared to antibacterial functionality. The study revealed that the incorporation of octanoyl (C8) and lauroyl (C12) group(s) at C-3 position of rhamnopyranoside possessed promising antimicrobial, and anti-carcinogenic potentiality with good pharmacokinetic (pkCSM), and drug likeness properties. Also, attachment of multiple ester groups enhanced various drug likeness, and medicinal chemistry friendliness conditions. Overall, the present findings might be useful for the development of rhamnopyranoside based novel MDR antimicrobial drugs.
    [Show full text]
  • Biomolecules
    biomolecules Communication MBLinhibitors.com, a Website Resource Offering Information and Expertise for the Continued Development of Metallo-β-Lactamase Inhibitors Zishuo Cheng 1, Caitlyn A. Thomas 1, Adam R. Joyner 2, Robert L. Kimble 1, Aidan M. Sturgill 1 , Nhu-Y Tran 1, Maya R. Vulcan 1, Spencer A. Klinsky 1, Diego J. Orea 1, Cody R. Platt 2, Fanpu Cao 2, Bo Li 2, Qilin Yang 2, Cole J. Yurkiewicz 1, Walter Fast 3 and Michael W. Crowder 1,* 1 Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA; [email protected] (Z.C.); [email protected] (C.A.T.); [email protected] (R.L.K.); [email protected] (A.M.S.); [email protected] (N.-Y.T.); [email protected] (M.R.V.); [email protected] (S.A.K.); [email protected] (D.J.O.); [email protected] (C.J.Y.) 2 Department of Computer Science and Software Engineering, Miami University, Oxford, OH 45056, USA; [email protected] (A.R.J.); [email protected] (C.R.P.); [email protected] (F.C.); [email protected] (B.L.); [email protected] (Q.Y.) 3 Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy and the LaMontagne Center for Infectious Disease, University of Texas, Austin, TX 78712, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-513-529-2813 Received: 17 February 2020; Accepted: 12 March 2020; Published: 16 March 2020 Abstract: In an effort to facilitate the discovery of new, improved inhibitors of the metallo-β-lactamases (MBLs), a new, interactive website called MBLinhibitors.com was developed.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Recreating Ancient Metabolic Pathways Before Enzymes Kamila B
    Recreating ancient metabolic pathways before enzymes Kamila B. Muchowska, Elodie Chevallot-Beroux, Joseph Moran To cite this version: Kamila B. Muchowska, Elodie Chevallot-Beroux, Joseph Moran. Recreating ancient metabolic path- ways before enzymes. Bioorganic and Medicinal Chemistry, Elsevier, 2019, 27 (12), pp.2292-2297. 10.1016/j.bmc.2019.03.012. hal-02516541 HAL Id: hal-02516541 https://hal.archives-ouvertes.fr/hal-02516541 Submitted on 23 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Graphical Abstract To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered. Recreating ancient metabolic pathways Leave this area blank for abstract info. before enzymes Kamila B. Muchowskaa* , Elodie Chevallot-Berouxa, and Joseph Morana* University of Strasbourg, CNRS, ISIS UMR 7006, 67000 Strasbourg, France Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com Recreating ancient metabolic pathways before enzymes Kamila B. Muchowska,a* Elodie Chevallot-Beroux,a and Joseph Morana* a University of Strasbourg, CNRS, ISIS UMR 7006, 67000 Strasbourg, France. ARTICLE INFO ABSTRACT Article history: The biochemistry of all living organisms uses complex, enzyme-catalyzed metabolic reaction Received networks.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]